Theodore J Cory1, Susan E Birket2, Brian S Murphy3, Don Hayes4, Michael I Anstead5, Jamshed F Kanga5, Robert J Kuhn6, Heather M Bush7, David J Feola8. 1. Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, 789 S. Limestone, Lexington, KY 40536, United States; Department of Pharmacy Practice, University of Nebraska College of Pharmacy, 986000 Nebraska Medical Center, Omaha, NE 68198, United States. 2. Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, 789 S. Limestone, Lexington, KY 40536, United States; Department of Medicine, University of Alabama at Birmingham, 1918 University Blvd., Birmingham, AL 35294, United States. 3. Department of Internal Medicine, University of Kentucky College of Medicine, 138 Leader Avenue, Lexington, KY 40506, United States. 4. Section of Pulmonary Medicine, Department of Pediatrics, The Ohio State University, Nationwide Children's Hospital, 700 Children's Dr., Columbus, OH 43205, United States. 5. Department of Pediatrics, University of Kentucky, 138 Leader Avenue, Lexington, KY 40506, United States. 6. Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, 789 S. Limestone, Lexington, KY 40536, United States. 7. Department of Biostatistics, University of Kentucky College of Medicine, 725 Rose Street, Lexington, KY 40536, United States. 8. Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, 789 S. Limestone, Lexington, KY 40536, United States. Electronic address: david.feola@uky.edu.
Abstract
BACKGROUND: Azithromycin treatment improves clinical parameters in patients with CF, and alters macrophage activation from a pro-inflammatory (M1) phenotype to a pro-fibrotic, alternatively activated (M2) phenotype. The transcriptional profile of cells from patients receiving azithromycin is unknown. METHODS: Gene expression in association with macrophage polarization, inflammation, and tissue remodeling was assessed from sputum samples collected from patients with CF. Transcriptional profiles and clinical characteristics, including azithromycin therapy, were compared. RESULTS: Expression of NOS2 and TNFα was decreased in subjects receiving azithromycin, whereas expression of M2-associated genes was unaffected. Principal component analysis revealed gene expression profiles consistent with M1- (MMP9, NOS2, and TLR4) or M2-polarization (CCL18, fibronectin, and MR1) in select subject groups. These expression signatures did not significantly correlate with clinical characteristics. CONCLUSIONS: Pro-inflammatory gene expression was low in subjects receiving AZM. Genes were stratified into groupings characteristic of M1- or M2-polarization, suggesting that overall polarization status is distinct among patient groups.
BACKGROUND:Azithromycin treatment improves clinical parameters in patients with CF, and alters macrophage activation from a pro-inflammatory (M1) phenotype to a pro-fibrotic, alternatively activated (M2) phenotype. The transcriptional profile of cells from patients receiving azithromycin is unknown. METHODS: Gene expression in association with macrophage polarization, inflammation, and tissue remodeling was assessed from sputum samples collected from patients with CF. Transcriptional profiles and clinical characteristics, including azithromycin therapy, were compared. RESULTS: Expression of NOS2 and TNFα was decreased in subjects receiving azithromycin, whereas expression of M2-associated genes was unaffected. Principal component analysis revealed gene expression profiles consistent with M1- (MMP9, NOS2, and TLR4) or M2-polarization (CCL18, fibronectin, and MR1) in select subject groups. These expression signatures did not significantly correlate with clinical characteristics. CONCLUSIONS: Pro-inflammatory gene expression was low in subjects receiving AZM. Genes were stratified into groupings characteristic of M1- or M2-polarization, suggesting that overall polarization status is distinct among patient groups.
Authors: Dmitri V Pechkovsky; Antje Prasse; Florian Kollert; Kathrin M Y Engel; Jan Dentler; Werner Luttmann; Karlheinz Friedrich; Joachim Müller-Quernheim; Gernot Zissel Journal: Clin Immunol Date: 2010-07-31 Impact factor: 3.969
Authors: Lisa Saiman; Michael Anstead; Nicole Mayer-Hamblett; Larry C Lands; Margaret Kloster; Jasna Hocevar-Trnka; Christopher H Goss; Lynn M Rose; Jane L Burns; Bruce C Marshall; Felix Ratjen Journal: JAMA Date: 2010-05-05 Impact factor: 56.272
Authors: David J Feola; Beth A Garvy; Theodore J Cory; Susan E Birket; Heather Hoy; Don Hayes; Brian S Murphy Journal: Antimicrob Agents Chemother Date: 2010-03-15 Impact factor: 5.191
Authors: Amarjit S Naura; Mourad Zerfaoui; Hogyoung Kim; Zakaria Y Abd Elmageed; Paulo C Rodriguez; Chetan P Hans; Jihang Ju; Youssef Errami; Jiwon Park; Augusto C Ochoa; A Hamid Boulares Journal: J Immunol Date: 2010-07-28 Impact factor: 5.422
Authors: Jean M Daley; Samielle K Brancato; Alan A Thomay; Jonathan S Reichner; Jorge E Albina Journal: J Leukoc Biol Date: 2010-01 Impact factor: 4.962
Authors: Brian S Murphy; Vidya Sundareshan; Theodore J Cory; Don Hayes; Michael I Anstead; David J Feola Journal: J Antimicrob Chemother Date: 2008-01-29 Impact factor: 5.790
Authors: D J McKeon; K A Cadwallader; S Idris; A S Cowburn; M C Pasteur; H Barker; C S Haworth; D Bilton; E R Chilvers; A M Condliffe Journal: Eur Respir J Date: 2009-10-19 Impact factor: 16.671
Authors: Magali Meyer; François Huaux; Ximena Gavilanes; Sybille van den Brûle; Patrick Lebecque; Sandra Lo Re; Dominique Lison; Bob Scholte; Pierre Wallemacq; Teresinha Leal Journal: Am J Respir Cell Mol Biol Date: 2009-02-24 Impact factor: 6.914
Authors: Sina A Gharib; Ryan S McMahan; William E Eddy; Matthew E Long; William C Parks; Moira L Aitken; Anne M Manicone Journal: J Allergy Clin Immunol Date: 2018-11-14 Impact factor: 10.793
Authors: Bei Zhang; William M Bailey; Timothy J Kopper; Michael B Orr; David J Feola; John C Gensel Journal: J Neuroinflammation Date: 2015-11-24 Impact factor: 8.322